Identification of Biomarkers That Can Predict Progression from Latent Tuberculosis Infection to Active Tuberculosis Disease

Study Location:

India

Topic:

Tuberculosis

Enrollment:

Open

Trial Period:

Ongoing

Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort (Cohort B). Immunological profiling of TB antigen induced biosignatures, profiling of transcriptional and proteomic biosignatures should provide novel insights into the nature of the immune response that differentiates progressors to TB disease from non-progressors. We aim to measure the plasma biomarker profiles and profile microRNAs at baseline in HHC who progress versus those who do not. We will also measure the unstimulated, TB-antigen and mitogen stimulated cytokine and chemokine responses and unstimulated, TB-antigen and mitogen stimulated growth factors and other immune factors at baseline in HHC who progress versus those who do not to elucidate the differential immune profile between the 2 groups. Our study should provide us new insights into the nature of the immune signatures that differentiate progressors from non-progressor in this cohort.

Aims:
The major objectives of the study are to identify biomarkers that can accurately predict progression from latent TB infection to active TB disease,
To measure the plasma biomarker profiles at baseline in HHC who progress versus those who do not.
To profile microRNAs at baseline in HHC who progress versus those who do not.
To measure the unstimulated, TB-antigen and mitogen stimulated cytokine and chemokine responses at baseline in HHC who progress versus those who do not.
To measure the unstimulated, TB-antigen and mitogen stimulated growth factors and other immune factors at baseline in HHC who progress versus those who do not.

Adult, Pediatric, Household contacts

Categories

Location
Topic

Clinical Trials

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

Read More

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More